Affiliation:
1. a Departments of Geriatric Medicine, Hospital General Universitario “Gregorio Marañón,” Madrid, Spain
2. b Departments of Preventive Medicine, Hospital General Universitario “Gregorio Marañón,” Madrid, Spain
3. c Departments of Oncology, Hospital General Universitario “Gregorio Marañón,” Madrid, Spain
Abstract
Abstract
Learning Objectives
After completing this course, the reader will be able to: Use patient age as only one consideration, along with tumor status and comorbidities, in deciding on treatment strategies for elderly colorectal cancer patients.Obtain and apply information regarding the medical, functional, mental, and social status of colorectal cancer elderly patients in order to make appropriate therapeutic decisions.
CME This article is available for continuing medical education credit at CME.TheOncologist.com
Purpose.
To analyze differences in the therapeutic approach to and tumor-related mortality of young and elderly colorectal cancer (CRC) patients.
Patients and Methods.
This was a descriptive study of a retrospective cohort, based on administrative databases, of all patients with CRC diagnosed or treated in our institution. We extracted data on sociodemographic characteristics, comorbidity, type of cancer, type of treatment received, survival time, and cause of death. We compared differences between a young group (YG) (age <75 years) and an older group (OG) (age ≥75 years) and assessed the variables associated with receiving different therapeutic options (multivariate analysis) and with survival time (Cox proportional hazards models).
Results.
The study included 503 patients (YG, 320; OG, 183), with mean ages of 63.1 years in the YG and 81.8 years in the OG. No differences were observed between the groups in degree of differentiation, extension, tumor stage, or comorbidity. After adjustment for gender, comorbidity, and tumor localization and extension, YG patients were more likely than OG patients to receive surgery, radiotherapy, and chemotherapy and less likely to receive palliative care. After a median follow-up of 36.5 months, YG patients had a longer tumor-specific survival time than OG patients (36.41 months vs 26.05 months). After further adjustment, the YG had a lower tumor-specific mortality risk (hazard ratio, 0.66) than the OG.
Conclusion.
In comparison with younger patients, elderly CRC patients are undertreated, mainly because of their age and not because of their tumor type or comorbidity. Elderly patients have a significantly shorter tumor-specific survival time, partially because of this undertreatment.
Publisher
Oxford University Press (OUP)